XORTX Therapeutics Inc. (XRTX)

Market Cap	45.98M
Revenue (ttm)	n/a
Net Income (ttm)	-7.78M
Shares Out	17.99M
EPS (ttm)	-4.27
PE Ratio	n/a
Forward PE	0.96
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,942
Open	2.750
Previous Close	2.590
Day's Range	2.530 - 2.765
52-Week Range	1.980 - 67.716
Beta	-0.15
Analysts	Strong Buy
Price Target	14.00 (+446.88%)
Earnings Date	May 14, 2024

About XRTX

XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and acute kidney injury (AKI) associated health consequences; an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 2
• Stock Exchange: NASDAQ
• Ticker Symbol: XRTX

Analyst Forecast

According to one analyst, the rating for XRTX stock is "Strong Buy" and the 12-month stock price forecast is $14.0.

Price Target

$14.0

(446.88% upside)

Analyst Consensus: Strong Buy